HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101

Excerpt from the Press Release:

SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / October 3, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from different solid tumors or hematological malignancies with significant unmet medical needs, today announced that the first patient has been dosed in a Phase 1, multi-regional, multi-center clinical trial (ClinicalTrials.gov ID: NCT05892718). The trial aims to evaluate the safety, tolerability, pharmacodynamics, and anti-tumor activity of HCB101 in patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.

“The dosing of the first patient with HCB101 marks another major milestone in evaluating the potential benefit of HCB101 for these patient populations,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “Based on the preclinical head-to-head comparison studies, HCB101 repeatedly demonstrated superior efficacy and excellent safety profiles in comparison with several similar biologics currently being investigated in clinical trials targeting the same SIRPα-CD47 pathway. I am immensely proud of the teamwork that has brought our differentiated program to this point with only 2.6 years from the Company’s inception to IND and now first-patient-in. HanchorBio is dedicated to discovering and developing immunotherapies to overcome the inadequacies of PD-1/L1 therapies with our proprietary FBDB™ technology platform.”

“There is an urgent need for new treatment options for patients with cancer, particularly those who cannot tolerate currently available therapies,” commented Jason Tsai, M.D., M.S., Chief Medical Officer of HanchorBio. “Through blockade of the SIRPα-CD47 pathway, HCB101 brings additional armament to fight cancer. Our goal is to bring transformative treatment options for patients with cancer by developing HCB101 as a foundational innate immunity checkpoint immunotherapy and open the door to innate-adaptive combination immuno-oncology therapy.”

HCB101 is an engineered fusion protein using the Company’s proprietary Fc-based designer biologics (FBDB™) technology platform that blocks the “do not eat” signal from the SIRPα-CD47 pathway, which inhibits the ability of macrophages to engulf and destroy cancer cells.

Click the button below to read the entire Press Release:

Continue Reading The Press Release